Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.

Carballo, Erica V; Pham, Tra V; Turashvili, Gulisa; Hanley, Krisztina; Starbuck, Kristen D; Meisel, Jane L

Carballo, Erica V; Pham, Tra V; Turashvili, Gulisa; Hanley, Krisztina; Starbuck, Kristen D; Meisel, Jane L.

Afiliación

Carballo EV; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States.
Pham TV; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States.
Turashvili G; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, United States.
Hanley K; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, United States.
Starbuck KD; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States.
Meisel JL; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States.

Gynecol Oncol Rep ; 43: 101062, 2022 Oct.

Article en En | MEDLINE | ID: mdl-36032811

Palabras clave

ALK fusion; ALK-inhibitor; Case report; TNS1-ALK fusion; Uterine inflammatory myofibroblastic tumor; Uterine leiomyosarcoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Gynecol Oncol Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google